Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NEXN antisense RNA 1 (NEXN-AS1) is a long non-coding RNA transcribed from a gene partially overlapping the protein-coding NEXN gene on chromosome 1. NEXN-AS1 upregulates NEXN, which encodes an actin-binding protein with roles in vascular cell function. NEXN-AS1 expression is reduced in atherosclerotic plaques, and its overexpression inhibits inflammatory responses, monocyte adhesion, and vascular smooth muscle cell proliferation and migration by upregulating NEXN and interacting with chromatin remodelers such as BAZ1A. Its anti-atherosclerotic functions involve suppression of TLR4-NFκB signaling and sequestration of miR-33a/b. Genetic variants in NEXN-AS1 are associated with susceptibility to diseases such as coronary artery disease and lung cancer[1][2][3][4][6]. NEXN-AS1 is considered a non-protein-coding regulatory RNA rather than a receptor or enzyme, but it is a validated regulator with therapeutic and biomarker potential in cardiovascular disease and some cancers[1][2][3][4].
Upregulation of NEXN expression, Suppression of TLR4-NFκB signaling, Molecular sponge for miR-33a/b, Chromatin interaction via BAZ1A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NEXN antisense RNA 1 (NEXN-AS1).